Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy

被引:92
|
作者
Devillier, Raynier [1 ]
Coso, Diane [1 ]
Castagna, Luca [1 ,2 ]
Rossi, Isabelle Brenot [3 ]
Anastasia, Antonella [2 ]
Chiti, Arturo [4 ]
Ivanov, Vadim [1 ]
Schiano, Jean Marc [1 ]
Santoro, Armando [2 ]
Chabannon, Christian [1 ,5 ,6 ]
Balzarotti, Monica [2 ]
Blaise, Didier [1 ,5 ,6 ]
Bouabdallah, Reda [1 ]
机构
[1] Inst J Paoli I Calmettes, Dept Hematol, Transplantat & Cell Therapy Program, F-13009 Marseille, France
[2] Ist Clin Humanitas, Humanitas Canc Ctr, Hematol Unit, Milan, Italy
[3] Inst J Paoli I Calmettes, Dept Nucl Med, F-13009 Marseille, France
[4] Ist Clin Humanitas, Humanitas Canc Ctr, Nucl Med Unit, Milan, Italy
[5] Inst J Paoli I Calmettes, INSERM, CBT 510, Ctr Invest Clin Biotherapie, F-13009 Marseille, France
[6] Univ Aix Marseille, Fac Med, Inst J Paoli I Calmettes, Marseille, France
来源
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2012年 / 97卷 / 07期
关键词
Hodgkin's lymphoma; PET; outcome; relapsed refractory; ASCT; HIGH-DOSE CHEMOTHERAPY; PROGNOSTIC-FACTORS; FDG-PET; DISEASE; MULTICENTER; FAILURE; SCORE;
D O I
10.3324/haematol.2011.056051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background High-dose chemotherapy followed by autologous stem cell transplantation is the standard treatment for relapsed and/or refractory Hodgkin's lymphoma although half of patients relapse after transplantation. Predictive factors, such as relapse within 12 months, Ann-Arbor stage at relapse, and relapse in previously irradiated fields are classically used to identify patients with poor outcome. Recently, 18-fluorodeoxyglucose positron emission tomography has emerged as a new method for providing information to predict outcome. The aim of this study was to confirm the predictive value of positron emission tomography status after salvage therapy and to compare single versus tandem autologous stem cell transplantation in patients with relapsed and/or refractory Hodgkin's lymphoma. Design and Methods We report a series of 111 consecutive patients with treatment-sensitive relapsed and/or treatment-refractory Hodgkin's lymphoma who achieved complete (positron emission tomography-negative group) or partial remission (positron emission tomography-positive group) at positron emission tomography evaluation after salvage chemotherapy and who underwent single or tandem autologous stem cell transplantation. Results Five-year overall and progression-free survival rates were 81% and 64%, respectively. There were significant differences in 5-year progression-free survival (79% versus 23%; P<0.001) and 5-year overall survival (90% versus 55%, P=0.001) between the positron emission tomography-negative and -positive groups, respectively. A complete response, as determined by positron emission tomography evaluation, after salvage therapy predicted significantly better 5-year overall survival rates in both intermediate (91% versus 50%; P=0.029) and unfavorable (89% versus 58%; P=0.026) risk subgroup analyses. In the positron emission tomography-positive subgroup, tandem transplantation improved 5-year progression-free survival from 0% (in the single transplantation group) to 43% (P=0.034). Multivariate analysis showed that positron emission tomography status (hazard ratio: 5.26 [2.57-10.73]) and tandem transplantation (hazard ratio: 0.39 [0.19-0.78]) but not risk factors at relapse (hazard ratio: 1.77 [0.80-3.92]) significantly influenced progression-free survival, while only tomography status significantly influenced overall survival (hazard ratio: 4.03 [1.38-11.75]). Conclusions In patients with relapsed/refractory Hodgkin's lymphoma responding to prior salvage therapy, positron emission tomography response at time of autologous stem cell transplantation favorably influences outcome and enables identification of patients requiring single or tandem transplantation.
引用
收藏
页码:1073 / 1079
页数:7
相关论文
共 50 条
  • [1] Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma
    Moskowitz, Alison J.
    Yahalom, Joachim
    Kewalramani, Tarun
    Maragulia, Jocelyn C.
    Vanak, Jill M.
    Zelenetz, Andrew D.
    Moskowitz, Craig H.
    BLOOD, 2010, 116 (23) : 4934 - 4937
  • [2] Current Status of Autologous Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Lymphoma
    Colpo, Anna
    Hochberg, Ephraim
    Chen, Yi-Bin
    ONCOLOGIST, 2012, 17 (01) : 80 - 90
  • [3] Outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin lymphoma patients in a centre from Turkey
    Sucak, Gulsan Turkoz
    Cakar, Merih Kizil
    Suyani, Elif
    Aki, Zeynep
    Altindal, Sermin
    Acar, Kadir
    HEMATOLOGY, 2013, 18 (05) : 269 - 276
  • [4] Outcome of autologous hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory Hodgkin's lymphoma
    Hazar, Volkan
    Kesik, Vural
    Aksoylar, Serap
    Karakukcu, Musa
    Ozturk, Gulyuz
    Kupesiz, Alphan
    Atas, Erman
    Oniz, Haldun
    Kansoy, Savas
    Unal, Ekrem
    Tanyeli, Atila
    Erbey, Fatih
    Elli, Murat
    Tacyildiz, Nurdan
    Karasu, Gulsun Tezcan
    Kocak, Ulker
    Anak, Sema
    Bengoa, Sebnem Yilmaz
    Sezgin, Gulay
    Atay, Didem
    Unal, Emel
    Uygun, Vedat
    Kurucu, Nilgun
    Kaya, Zuhre
    Yesilipek, Akif
    PEDIATRIC TRANSPLANTATION, 2015, 19 (07) : 745 - 752
  • [5] Potential Benefit of Involved-Field Radiotherapy for Patients With Relapsed-Refractory Hodgkin's Lymphoma With Incomplete Response Before Autologous Stem Cell Transplantation
    Levis, Mario
    Piva, Cristina
    Filippi, Andrea Riccardo
    Botto, Barbara
    Gavarotti, Paolo
    Pregno, Patrizia
    Nicolosi, Maura
    Freilone, Roberto
    Parvis, Guido
    Gottardi, Daniela
    Vitolo, Umberto
    Ricardi, Umberto
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01) : 14 - 22
  • [6] Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation
    Fernandez de Larrea, C.
    Martinez, C.
    Gaya, A.
    Lopez-Guillermo, A.
    Rovira, M.
    Fernandez-Aviles, F.
    Lozano, M.
    Bosch, F.
    Esteve, J.
    Nomdedeu, B.
    Montserrat, E.
    Carreras, E.
    ANNALS OF ONCOLOGY, 2010, 21 (06) : 1211 - 1216
  • [7] Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation
    Smeltzer, Jacob P.
    Cashen, Amanda F.
    Zhang, Qin
    Homb, Andrew
    Dehdashti, Farrokh
    Abboud, Camille N.
    DiPersio, John F.
    Stockerl-Goldstein, Keith E.
    Uy, Geoffrey L.
    Vij, Ravi
    Westervelt, Peter
    Bartlett, Nancy L.
    Fehniger, Todd A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (11) : 1646 - 1652
  • [8] Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma
    Sirohi, B.
    Cunningham, D.
    Powles, R.
    Murphy, F.
    Arkenau, T.
    Norman, A.
    Oates, J.
    Wotherspoon, A.
    Horwich, A.
    ANNALS OF ONCOLOGY, 2008, 19 (07) : 1312 - 1319
  • [9] Current Role of Autologous and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
    Castagna, Luca
    Carlo-Stella, Carmelo
    Mazza, Rita
    Santoro, Armando
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2015, 7
  • [10] The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome
    Noring, Kristina
    Carlsten, Mattias
    Sonnevi, Kristina
    Wahlin, Bjorn Engelbrekt
    BMC CANCER, 2021, 21 (01)